COMBINATION THERAPY WITH ANTICANCER ALKALOID

FIELD: pharmaceutical industry.SUBSTANCE: group of inventions relates to the use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor for treating cancer. Use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor for treating cancer, where the topoisomerase I and/or II inhibitor is topotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, hepatoma, colorectal cancer, kidney cancer and brain cancer, and wherein the topoisomerase I and/or II inhibitor is irinotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, ovarian cancer and breast cancer. Use of a therapeutically effective amount of PM01183 or a pharmaceutically acceptable salt thereof in a combination with a therapeutically effective amount of a topoisomerase I and/or II inhibitor in the manufacture of a drug for treating cancer, where the topoisomerase I and/or II inhibitor is topotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, hepatoma, colorectal cancer, kidney cancer and brain cancer, and wherein the topoisomerase I and/or II inhibitor is irinotecan, when the cancer to be treated is selected from lung cancer, malignant melanoma, prostate cancer, pancreatic cancer, ovarian cancer and breast cancer.EFFECT: application described above synergistically increases efficacy of therapeutic treatment of cancer.6 cl, 296 dwg, 26 tbl, 19 ex Группа изобретений относится к фармацевтической промышленности, а именно к применению терапевтически эффективного количества РМ01183 или его фармацевтически приемлемой соли в комбинации с терапевтически эффективным количеством ингибитора топоизомеразы I и/или II для лечения рака. Применение терапевтически эффективного количества РМ01183 или его фармацевтически приемлемой соли в комбинации с терапевтически эффективным количеством ингибитора топоизомеразы I и/или II для лечения рака, где ингибитор топоизомеразы I и/или II представляет собой топотекан, когда рак, подлежащий лечению, выбран из рака легкого, злокачественной меланомы, р